Revision as of 13:27, 5 October 2017 edit Pkkaiser (talk \| contribs) 1 edit m a new scFV with positive phase3 results Tag: Visual edit ← Previous edit		Revision as of 11:46, 11 October 2017 edit undo Anypodetos (talk \| contribs) Autopatrolled, Extended confirmed users, Pending changes reviewers, Rollbackers 39,350 edits m →Examples: Wikilink Next edit →
Line 20: * [[Pexelizumab]], a scFv binding to [[Complement component 5\|component 5]] of the [[complement system]] and used to reduce side effects of [[cardiac surgery]]<ref>{{cite journal\|pmid=15331798\|year=2004\|last1=Mathew\|first1=JP\|last2=Shernan\|first2=SK\|last3=White\|first3=WD\|last4=Fitch\|first4=JC\|last5=Chen\|first5=JC\|last6=Bell\|first6=L\|last7=Newman\|first7=MF\|title=Preliminary report of the effects of complement suppression with pexelizumab on neurocognitive decline after coronary artery bypass graft surgery\|volume=35\|issue=10\|pages=2335–9\|doi=10.1161/01.STR.0000141938.00524.83\|journal=Stroke; a journal of cerebral circulation}}</ref> * C6.5, a diabody targeting [[HER2/neu]]<ref name="Adams" /> found in some [[breast cancer]]s * [[Brolucizumab]], a scFV binding to VEGF-A and used to treat wet age-related macular degeneration ==References==

Single-chain variable fragment: Difference between revisions